Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer. Please visit www.ceptaris.com for more information.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/21/12 | $15,000,000 |
Oxford Finance Silicon Valley Bank | undisclosed | |
| 06/05/12 | $10,000,000 | Series D-1 |
Aperture Venture Partners BioAdvance Osage Venture Partners Palo Alto Investors Third Point Ventures Vivo Ventures | undisclosed |
